



March 20, 2025

The Manager
BSE Limited
Corporate Relationship Department
P. J. Towers, Dalal Street,
Mumbai – 400 001.

The Manager
The National Stock Exchange of India Limited Exchan
Plaza,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051.

BSE Scrip Code No. 524280

NSE Symbol: KOPRAN

Dear Sir/Madam,

Re: Disclosure pursuant to Regulation 30 read with Schedule III and Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 (“SEBI LODR”)

Sub: Outcome of Board Meeting held on March 20, 2025

Pursuant to Regulation 30 and 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors of Kopran Limited (‘the Company’) in its meeting held at the Registered Office of the Company on Thursday, March 20, 2025 has inter alia, considered & approved the following matters:

1. Merger:

The Board on recommendation of Audit Committee and Committee of Independent Directors meeting(s) held on March 20, 2025 has approved the Merger of Kopran Laboratories Limited (CIN: U24230MH1986PLC040602), a promoter group company with Kopran Limited (CIN: L24230MH1958PLC011078) (“Company”) subject to relevant provisions of Companies Act, 2013 and Securities Exchange Board of India, Regulations

The details as required under Regulation 30 of the SEBI LODR Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 is enclosed herewith and marked as **Annexure A**.

Kindly publish disclosures on exchange websites.

The Board Meeting commenced at HH:MM 12:30 & concluded at HH:MM 15.15

Regards,
For Kopran Limited

Sunil Sodhani
Company Secretary & Compliance Officer
Membership No. FCS 3897

Encl: As above



KOPRAN LTD.: Parijat House, 1076, Dr. E. Moses Road, Worli, Mumbai - 400 018. P. B. No. 9917, Tel.: (022) 4366 1111
Fax: (022) 2495 0363 Website: www.kopran.com CIN – L 24230 MH 1958 PLC 011078. E-mail: cs@kopran.com
Works: • Village Savroli, Taluka: Khalapur, District: Raigad - 410 202. Tel.: (02192) 274500 / 335 / 337 • Fax: (02192) 274025

Annexure A

**DISCLOSURE REQUIRED UNDER REGULATION 30 OF THE SEBI LODR REGULATIONS
READ WITH SEBI MASTER CIRCULAR SEBI/HO/CFD/PoD2/CIR/P/0155 dated
November 11, 2024:**

Particulars	Disclosures																								
Name of the entity(ies) forming part of the amalgamation / merger, details in brief such as, size, turnover, etc	<p>There is a proposal for Amalgamation of Kopran Laboratories Limited (Transferor Company) with Kopran Limited (Transferee Company) and their respective shareholders and creditors. The transaction is proposed to be implemented through a Scheme of Amalgamation under the provisions of Companies Act, 2013 and other applicable provisions, if any (herein referred to as “The Proposed Scheme of Amalgamation”/ “The Proposed Scheme”)</p> <p>Brief Financial details of the Transferor Company and Transferee Company is provided Below:</p> <p>1. Kopran Laboratories Limited (Transferor Company)</p> <table border="1" style="margin-left: 40px;"> <thead> <tr> <th style="text-align: left;">Particulars</th> <th style="text-align: right;">As on December 31, 2024 Audited (Rs. In Lakhs)</th> </tr> </thead> <tbody> <tr> <td>Paid up Capital</td> <td style="text-align: right;">530.32</td> </tr> <tr> <td>Net worth</td> <td style="text-align: right;">7259.27</td> </tr> <tr> <td>Turnover</td> <td style="text-align: right;">6960.64</td> </tr> </tbody> </table> <p>2. Kopran Limited (Transferee Company)</p> <table border="1" style="margin-left: 40px;"> <thead> <tr> <th style="text-align: left;">Particulars</th> <th style="text-align: right;">As on March 31, 2024 Audited (Rs. In Lakhs)</th> </tr> </thead> <tbody> <tr> <td>Paid up Capital</td> <td style="text-align: right;">4821.26</td> </tr> <tr> <td>Net worth*</td> <td style="text-align: right;">49124.50</td> </tr> <tr> <td>Turnover*</td> <td style="text-align: right;">62920.27</td> </tr> </tbody> </table> <table border="1" style="margin-left: 40px;"> <thead> <tr> <th style="text-align: left;">Particulars</th> <th style="text-align: right;">As on December 31, 2024 Unaudited (Rs. In Lakhs)</th> </tr> </thead> <tbody> <tr> <td>Paid up Capital</td> <td style="text-align: right;">4824.94</td> </tr> <tr> <td>Net worth*</td> <td style="text-align: right;">5087.48</td> </tr> <tr> <td>Turnover*</td> <td style="text-align: right;">45724.13</td> </tr> </tbody> </table> <p>*Consolidated Basis</p>	Particulars	As on December 31, 2024 Audited (Rs. In Lakhs)	Paid up Capital	530.32	Net worth	7259.27	Turnover	6960.64	Particulars	As on March 31, 2024 Audited (Rs. In Lakhs)	Paid up Capital	4821.26	Net worth*	49124.50	Turnover*	62920.27	Particulars	As on December 31, 2024 Unaudited (Rs. In Lakhs)	Paid up Capital	4824.94	Net worth*	5087.48	Turnover*	45724.13
Particulars	As on December 31, 2024 Audited (Rs. In Lakhs)																								
Paid up Capital	530.32																								
Net worth	7259.27																								
Turnover	6960.64																								
Particulars	As on March 31, 2024 Audited (Rs. In Lakhs)																								
Paid up Capital	4821.26																								
Net worth*	49124.50																								
Turnover*	62920.27																								
Particulars	As on December 31, 2024 Unaudited (Rs. In Lakhs)																								
Paid up Capital	4824.94																								
Net worth*	5087.48																								
Turnover*	45724.13																								



Kopran

Details of Pre-Shareholding							
Promoter and Promoter Group		Public		Others		Total	
Number of shares*	Percentage*	Number of shares*	Percentage*	Number of shares*	Percentage*	Number of shares*	Percentage*
21449203	44.46	26799702	55.54	500	0.00	48249405	100.00

Details of Post Shareholding							
Promoter and Promoter Group		Public		Others		Total	
Number of shares*	Percentage*	Number of shares*	Percentage*	Number of shares*	Percentage*	Number of shares*	Percentage*
33234003	55.36	26799702	44.64	500	0.00	60034205	100.00

Whether the transaction falls within related party transaction? If yes, whether the same is done at 'arm's length'.	The Transaction will fall within the ambit of related party transactions. Yes, the proposed transaction will be done at arm's length
Date of board meeting in which RPT approval taken	March 20, 2025
Date of audit committee meeting in which RPT approval taken	March 20, 2025
Whether the said RPT is material? *	Yes
Date of approval from shareholders	Shareholders' approval Shall be taken in due course





Kopran

Whether the promoter/ promoter group/ group/associate/holding/subsidiary companies/ Director & KMP and its relatives have any interest in the entity being acquired? *	Yes.
Nature of interest and details thereof	Promoters of the Company are holding 100% shares of Kopran Laboratories Limited hence they are deemed to be interested.
Whether the same is done at "arm's length" *	Yes, The transaction is done after considering the Valuation report from the Registered Valuer and Fairness Opinion from the Category -I Merchant Banker.
Date of Special Resolution	Not applicable
Area of business of the entity(ies)	Transferee Company: Kopran Limited It is primarily engaged in the business of manufacturing of Finished Dosage Forms and Active pharmaceutical ingredients (APIs). Transferor Company: Kopran Laboratories Limited It is engaged in the business of Marketing diagnostic equipment's, consumables and automations solutions to path labs and hospitals.
Rationale for amalgamation/ merger	a) In order to consolidate the different segments of business in the Healthcare industry carried on by the Companies and effectively manage the Transferor Company and Transferee Company as a single entity which shall provide several benefits including streamlined group structure by reducing the number of legal entities and reducing the multiplicity of legal and regulatory compliances, rationalizing costs, it is intended to amalgamate the Transferor Company with the Transferee Company in accordance with the terms hereof. b) In particular, the scheme is expected to have the following benefits: (i) The merger will allow Transferee Company to capitalize on





Kopran

	<p>Transferor Company's relationships and team for marketing Transferee Company's product into hospitals and government institutions.</p> <p>(ii) Transferee Company will leverage its manufacturing capabilities to repack and manufacture diagnostic kits thereby increasing margins and profitability.</p> <p>(iii) This will take Transferee Company one step further in becoming an integrated health care and pharma company.</p> <p>(iv) Benefit to the shareholders, employees and other stakeholders of the respective companies by consolidating and simplifying the group structure, and business operations.</p> <p>(v) Enable pooling of resources and provide optimal utilization of financial, human or other resources;</p> <p>(vi) Economies in administrative and managerial costs by consolidating operations and would substantially reduce duplication of administrative responsibilities and multiplicity of records and legal and regulatory compliances;</p> <p>(vii) Enhance growth prospects, reduce overheads, administrative, managerial and other costs and expenditure and remove inefficiencies and bring operational rationalization and organizational efficiency;</p> <p>(viii) Build strong capability to effectively meet future challenges in competitive business environment;</p> <p>(ix) Result in improved shareholder value for the shareholders of the respective companies, thus providing a stronger and wider capital and financial base for future growth /expansion of the Transferee Company.</p>
Consideration*	Issue of shares
Details of consideration	Swap Ratio: "100 (One Hundred) fully paid Equity Shares of INR 10 each of





Kopran

	Kopran Limited (Transferee Company) against 45 (Forty-Five) Equity Share of INR 10 of Kopran Laboratories Limited(Transferor Company) to each of the equity shareholder holding fully paid-up Equity Shares in the Transferor Company and whose name is recorded in the Register of Members of Transferor Company as on the record date.”				
In case of cash consideration amount otherwise share exchange ratio	There shall be no cash consideration in the proposed scheme of Amalgamation.				
Brief details of change in shareholding pattern (if any) of listed entity*	Kopran Limited (Transferee Company)				
	Particulars	Pre		Post	
		No. of shares	%	No. of shares	%
	Promoters	2,14,49,203	44.46	33234003*	55.36
	Public	2,67,99,702	55.54	26799702	44.64
	Others	1000	0.00	500	00.00
	Total	4,82,49,405	100.00	60034205	100.00
	* Post shareholding of Promoters includes 1.44% shares of Kopran Laboratories Limited are under transfer to the Promoters of Kopran Laboratories Limited.				
Any other significant information (in brief)*	----				

